BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oo WM, Hunter DJ. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210902. [DOI: 10.1177/1759720x221090297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Staebler S, Lichtblau A, Gurbiel S, Schubert T, Riechers A, Rottensteiner-Brandl U, Bosserhoff A. MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy. Cells 2023;12. [PMID: 36672165 DOI: 10.3390/cells12020229] [Reference Citation Analysis]
2 Tenti S, Bruyère O, Cheleschi S, Reginster JY, Veronese N, Fioravanti A. An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Ther Adv Musculoskelet Dis 2023;15:1759720X231158618. [PMID: 36937821 DOI: 10.1177/1759720X231158618] [Reference Citation Analysis]
3 Schäfer N, Grässel S. Targeted therapy for osteoarthritis: progress and pitfalls. Nat Med 2022;28:2473-5. [PMID: 36456832 DOI: 10.1038/s41591-022-02057-x] [Reference Citation Analysis]
4 García-Couce J, Schomann T, Chung CK, Que I, Jorquera-Cordero C, Fuentes G, Almirall A, Chan A, Cruz LJ. Thermosensitive Injectable Hydrogels for Intra-Articular Delivery of Etanercept for the Treatment of Osteoarthritis. Gels 2022;8:488. [PMID: 36005089 DOI: 10.3390/gels8080488] [Reference Citation Analysis]
5 Oo WM, Mobasheri A, Hunter DJ. A narrative review of anti-obesity medications for obese patients with osteoarthritis. Expert Opin Pharmacother 2022. [PMID: 35855642 DOI: 10.1080/14656566.2022.2104636] [Reference Citation Analysis]